Legend Biotech Is Said to Weigh Second Listing Outside of US (1)

Legend Biotech Corp. is considering a second listing outside of the US, according to people familiar with the matter, as investors show a strong appetite for drugmakers.

The New Jersey-headquartered company, which has been developing a cell therapy cancer drug with Johnson & Johnson, has discussed the second listing option with potential advisers, the people said, asking not to be identified because the talks are private. Possible venues include Hong Kong, Singapore and London, they said.

A second listing could help to boost Legend’s valuation, particularly if it takes place in Hong Kong, the people said. The city’s Hang ...